title: A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy.
abstract: In a cross-sectional study of aviremic neurocognitively impaired patients receiving protease inhibitors as triple-drug therapy (n = 30) or as monotherapy (n = 22), we found no statistically significant differences in the types of cognitive domains involved or severity of cognitive deficit. Cerebrospinal fluid concentrations of total proteins, total tau, myelin basic protein, neuron-specific enolase, β2 microglobulin, S100B protein, or prevalence of cerebrospinal fluid HIV-RNA detection by standard (6.3% vs 7.1% P = 1) or ultrasensitive assays (50% vs 71.4%, P = 0.28) were similar in both groups. These results do not suggest important differences in the pattern of neurocognitive impairment between groups receiving very different antiretroviral strategies.
authors.affiliation: *HIV Unit, Internal Medicine Service, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; †Microbiology Service, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; ‡Psychiatry Service, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; and §Clinical Pharmacology Service, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (Dr Lakatos is now with Department of Infectious Diseases, Saint Laszlo Teaching Hospital of Semmelweis University, Budapest, Hungary).
authors.forename: Miriam
authors.initials: M
authors.lastname: Estébanez
authors.forename: Natalia
authors.initials: N
authors.lastname: Stella-Ascariz
authors.forename: Jesús
authors.initials: J
authors.lastname: Mingorance
authors.forename: Ignacio
authors.initials: I
authors.lastname: Pérez-Valero
authors.forename: Alicia
authors.initials: A
authors.lastname: González-Baeza
authors.forename: Carmen
authors.initials: C
authors.lastname: Bayón
authors.forename: Botond
authors.initials: B
authors.lastname: Lakatos
authors.forename: Alberto
authors.initials: A
authors.lastname: Borobia
authors.forename: Francisco
authors.initials: F
authors.lastname: Arnalich
authors.forename: José R
authors.initials: JR
authors.lastname: Arribas
mesh_terms: D015526:AIDS Dementia Complex / Q000188:drug therapy*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D003430:Cross-Sectional Studies; D000069454:Darunavir; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D061466:Lopinavir; D000069454:Darunavir